Sigyn Therapeutics explores NASDAQ merger, establishes clinical pathway
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
January 15, 2026 11:01 AM ESTSAN DIEGO, CA - January 15, 2026 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released the following shareholder update authored by Chief Executive Officer, Jim Joyce.
Dear Shareholders and Interested Parties,
Cardiovascular disease is the #1 cause of death worldwide. The primary aim of treatment is to reduce major adverse cardiovascular events (MACE).
The leading class of drugs to treat cardiovascular disease are statins, which reduce the incidence of MACE by approximately 25%. In contrast, blood purification therapies (lipoprotein apheresis) can... More
